CANADIAN ORDERS ONLY AT THIS TIME
FOR LABORATORY RESEARCH ONLY
← Back to home

MGMT RESEARCH · RETROD

Retatrutide (RETROD): Research Basics & Vial Calculations

A clear introduction to retatrutide research, preparation terminology and concentration calculations for our 10 mg and 20 mg vials.

Illustrative brunette researcher in an MGMT lab coat holding a RETROD vial and capped syringe against a softly blurred laboratory
Illustrative laboratory scene.
RETRODSearch retatrutide studies in PubMed

01. RETROD at a glance

RETROD is MGMT Research’s name for retatrutide. Our vial options are 10 mg and 20 mg of lyophilized research material. The amount on the label is the total compound in the vial; it is not a sample size or a syringe measurement.

Retatrutide activates three receptor pathways: GLP-1, GIP and glucagon. [1] Published human studies investigate its effects on body weight and metabolic outcomes. Study findings concern the trial material and protocol, and do not establish the identity, purity or suitability of a separately supplied research vial.

02. Before you begin

Start with the vial label, the applicable batch documentation and your laboratory’s approved procedure. Confirm the compound name, quantity, lot identifier and expiry before preparing a sample.

  • RETROD 10 mg or 20 mg vial
  • Protocol-compatible diluent and a suitable measuring device
  • New sterile syringes and needles where required by the procedure
  • Alcohol preparation pads, a clean work surface and appropriate protective equipment
  • A sharps container and a preparation record

Check the COA & Batch Reports page for the report corresponding to your lot. A pending report is not a completed test result.

03. BAC water: what the label tells you

Our BAC Water product is supplied in a 3 mL vial. Check the container label for its composition, storage conditions and handling instructions. The amount supplied is not automatically the amount to add to a RETROD vial.

Bacteriostatic water contains a preservative, but that does not make a contaminated preparation sterile. A diluent’s expiry also does not establish the stability of a compound mixed with it. Confirm compatibility and the required final volume in the research protocol. [3]

Single-dose and multidose containers have different handling requirements. CDC guidance for opened multidose medication vials is generally 28 days unless the manufacturer specifies otherwise, and never beyond the original expiry; this is not evidence that a reconstituted RETROD sample remains stable for 28 or 56 days. [2]

04. Reconstitution workflow

Reconstitution means adding the specified diluent to a freeze-dried material to prepare a solution. Follow the supplier’s validated instructions and your laboratory procedure for the actual preparation.

  1. Identify: verify the vial quantity, lot and diluent.
  2. Calculate: record the intended final concentration and volume before opening containers.
  3. Prepare: use a clean designated work area and aseptic technique.
  4. Mix: use the validated addition and mixing method; do not improvise heating or agitation.
  5. Inspect and record: document appearance, final volume, preparation date, storage conditions and the protocol-defined use period.

Visible particles, damage or suspected contamination require investigation. A clear solution alone does not prove sterility or potency.

Reconstitution & concentration guide →

05. 10 mg and 20 mg concentration charts

These are laboratory calculation examples, using a final solution volume of 2 mL. They do not select a human dose or establish a validated mixing procedure. Use the actual final volume specified by your protocol. Calculations use nominal label mass; they do not verify purity, recovery or the measured concentration of a preparation.

10 mg vial / 2 mL5 mg/mL0.05 mg per U-100 unit
20 mg vial / 2 mL10 mg/mL0.10 mg per U-100 unit
Sample mass at a 2 mL final volume
U-100 markingVolume10 mg vial20 mg vial
5 units0.05 mL0.25 mg0.5 mg
10 units0.10 mL0.5 mg1 mg
20 units0.20 mL1 mg2 mg
25 units0.25 mL1.25 mg2.5 mg
50 units0.50 mL2.5 mg5 mg
100 units1.00 mL5 mg10 mg

Example: 20 mg in a final volume of 2 mL gives 10 mg/mL. A 2 mg laboratory sample occupies 0.20 mL, corresponding to 20 units on a U-100 scale.

Changing the volume changes every conversion. For example, 10 mg in 1 mL and 20 mg in 2 mL both give 10 mg/mL.

Open the reconstitution calculator →

06. Understanding mg, mL and syringe units

mg measures compound mass. mL measures liquid volume. U-100 markings represent a volume scale: 100 units correspond to 1 mL. They are not universal “peptide units.” [4]

Concentration (mg/mL) = compound mass (mg) ÷ final volume (mL)
Sample volume (mL) = sample mass (mg) ÷ concentration (mg/mL)
U-100 marking = sample volume (mL) × 100

Check the scale and capacity of the actual device. Follow its manufacturer’s instructions for reading the plunger position. Do not estimate between markings that the device cannot reliably resolve.

07. What published dosing research actually studied

The 2023 phase 2 trial below is a selected teaching example. Later phase 3 publications are covered in our long-term research guide; the phase 2 table is not a complete account of current research.

The 2023 phase 2 obesity trial enrolled 338 adults and studied once-weekly retatrutide at target doses of 1, 4, 8 or 12 mg. The 4 mg and 8 mg groups included different starting-dose regimens; the 12 mg group began at 2 mg. These were monitored study arms, not a universal beginner schedule. [1]

At 48 weeks, mean weight changes were −8.7%, −17.1%, −22.8% and −24.2% in those respective target-dose groups, compared with −2.1% with placebo. These are study averages, not individual promises. [1]

A number falling between studied doses does not automatically make that number an independently tested regimen. Community “beginner,” “intermediate” and “advanced” schedules, split dosing and maintenance routines should not be treated as conclusions of this trial. This guide does not provide a self-administration or dose-escalation plan.

08. Side effects and considerations

In that phase 2 trial, gastrointestinal adverse events were the most common. They were dose-related and generally mild to moderate. Lower starting doses partly reduced these events. Dose-dependent increases in heart rate were also reported. [1]

Trial monitoring and participant eligibility matter when interpreting tolerability. A research guide cannot determine whether a compound, combination or schedule is appropriate for an individual. Questions about personal treatment, missed doses or symptoms belong with a qualified clinician.

09. Storage and preparation records

Supplier-provided storage guidance

This guidance applies to MGMT’s supplied peptide vials. Follow the actual product label and any batch-specific instructions.

Before reconstitution · lyophilized powder

Our supplier advises refrigeration at 2–8 °C for shorter-term storage and freezer storage when the powder will not be reconstituted soon. Confirm the freezer temperature in the product-specific storage instructions.

The supplier-stated estimates for lyophilized material are 12–18 months refrigerated and up to 24 months frozen. These are not independently verified stability results. Never exceed the expiry date on the label; receiving or freezing a vial does not restart its shelf life.

After reconstitution · prepared solution

For MGMT’s supplied formulations, our supplier advises keeping the prepared solution at 2–8 °C, protected from light, without freezing. This is product-specific guidance, not a rule for every peptide solution.

MGMT sets a maximum of three months after reconstitution. Follow any shorter limit specified by the product label, supplier, or validated laboratory procedure. This cap does not establish stability or microbiological suitability for three months.

If no preparation-specific storage period has been established, do not assume the solution can be kept for three months. The powder’s expiry does not establish a use-by date for the prepared solution.

Follow the storage conditions on the actual product label and the validated procedure for the preparation. Do not transfer a shelf-life claim from another supplier, a different formulation or an unopened diluent to your mixed sample.

Record the compound, lot, mass, diluent, final volume, concentration, preparation date, storage conditions and applicable use-by limit.

Use a new sterile needle and syringe when accessing a vial as required by aseptic practice, keep preparation areas clean, and discard material when sterility is questionable. Dispose of sharps in an appropriate container. [2]

10. Common calculation mistakes

  • Using a chart for a different vial quantity.
  • Confusing the 3 mL BAC Water supply vial with the final volume of the prepared solution.
  • Treating mg and mL as interchangeable.
  • Using U-100 conversions with a different syringe scale.
  • Changing the diluent volume without recalculating concentration.
  • Confusing the number of theoretical samples with a validated storage period.

11. Quick questions

Does a 20 mg vial mean a 20 mg sample?

No. It describes the total compound mass supplied in the vial.

Does adding more water add more compound?

No. It increases volume and reduces concentration; total compound mass remains the same, assuming no preparation losses.

How many 2 mg laboratory samples are in 20 mg?

The theoretical calculation is 20 ÷ 2 = 10 samples, before preparation and transfer losses. It says nothing about how long a preparation can be stored.

Does this guide confirm a batch is tested?

No. Refer to the individual lot’s published report and status in COA & Batch Reports.

12. Glossary and sources

Lyophilized: freeze-dried material.
Reconstitution: preparing a solution from a dry material using an appropriate diluent.
Concentration: compound mass per unit of solution volume.
Aliquot: a measured portion of a sample.
Agonist: a substance that activates a receptor.
COA: certificate of analysis for the identified sample or batch.

Primary references

  1. Peer-reviewed studyJastreboff et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. NEJM, 2023.
  2. Official guidanceCDC: Preventing Unsafe Injection Practices.
  3. Manufacturer labelingHospira. Bacteriostatic Water manufacturer labeling: compatibility and preparation-specific handling.
  4. Official safety alertFDA. Measurement errors involving milligrams, millilitres and syringe units.

Research context and concentration examples are provided for education. MGMT Research products are for laboratory research only, not for human or veterinary use.

Retatrutide long-term research →

↑ Back to top
MGMT RESEARCH

Your cart

Subtotal

Prices are in CAD. Tax and shipping are calculated at checkout.

Continue to checkout

E-transfer accepted. Credit cards coming soon.